Teserpaturev/G47Δ: First Approval

Fukuhara H, Ino Y, Todo T. Oncolytic virus therapy: a new era of cancer treatment at dawn. Cancer Sci. 2016;107:1373–9.

CAS  Article  Google Scholar 

Taguchi S, Fukuhara H, Todo T. Oncolytic virus therapy in Japan: progress in clinical trials and future perspectives. Jpn J Clin Oncol. 2019;49(3):201–9.

Article  Google Scholar 

Bommareddy PK, Shettigar M. Kaufman HL Integrating oncolytic viruses in combination cancer immunotherapy. Nat Rev Immunol. 2018;18:498–513.

CAS  Article  Google Scholar 

Fukuhara H, Takeshima Y, Todo T. Triple-mutated oncolytic herpes virus for treating both fast- and slow-growing tumors. Cancer Sci. 2021;112(8):3293–301.

CAS  Article  Google Scholar 

Zeng J, Li X, Sander M, et al. Oncolytic viro-immunotherapy: an emerging option in the treatment of gliomas. Front Immunol. 2021;12: 721830.

CAS  Article  Google Scholar 

Kaufman HL, Bommareddy PK. Two roads for oncolytic immunotherapy development. J Immunother Cancer. 2019;7:26.

Article  Google Scholar 

Mondal M, Guo J, He P, et al. Recent advances of oncolytic virus in cancer therapy. Hum Vaccines Immunother. 2020;16(10):2389–402.

CAS  Article  Google Scholar 

Ghouse JN, Martuza SM, Rabkin SD. In situ cancer vaccination and immunovirotherapy using oncolytic HSV. Viruses. 2021;13:1740.

Article  Google Scholar 

Mineta T, Rabkin SD, Yazaki T, et al. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med. 1995;1(9):938–43.

CAS  Article  Google Scholar 

Otani Y, Yoo JY, Shimizu T, et al. Implications of immune cells in oncolytic herpes simplex virotherapy for glioma. Brain Tumor Pathol. 2022;39(2):57–64.

Article  Google Scholar 

Todo T, Ito H, Ino Y, et al. Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial. Nat Med. 2022;28:1630-9.

Article  PubMed  PubMed Central  Google Scholar 

UMIN Clinical Trials Registry. Unique UMIN ID UMIN000015995. http://upload.umin.ac.jp. Accessed 29 July 2022.

Daiichi Sankyo Co. Ltd. DELYTACT® oncolytic virus G47∆ approved in Japan for treatment of patients with malignant glioma [media release]. 11 June 2021. https://www.daiichisankyo.com.

Daiichi-Sankyo Co. Ltd. DELYTACT: Japanese package insert. 2021.

Daiichi Sankyo Co. Ltd. Daiichi Sankyo launches DELYTACT(R) oncolytic virus G47 delta in Japan [media release]. 1 Nov 2021. https://www.daiichisankyo.com.

Daiichi Sankyo Co. Ltd. Oncolytic virus G47delta (DS-1647) designated as orphan drug under Orphan Drug/Medical Device designation system [media release]. http://www.daiichisankyo.com. Accessed 19 July 2021.

Daiichi Sankyo Co. Ltd. Daiichi Sankyo submits application for oncolytic virus teserpaturev (G47Δ) for treatment of patients with malignant glioma in Japan [media release]. http://www.daiichisankyo.com. Accessed 19 July 2021.

Daiichi Sankyo Co. Ltd. Reference data (consolidated financial results for Q3 FY2020). http://www.daiichisankyo.com. Accessed 29 July 2022.

Todo T, Martuza RL, Rabkin SD, et al. Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci USA. 2001;98:6396–401.

CAS  Article  Google Scholar 

Zhang W, Fulci G, Wakimoto H, et al. Combination of oncolytic herpes simplex viruses armed with angiostatin and IL-12 enhances antitumor efficacy in human glioblastoma models. Neoplasia. 2013;15(6):591–9.

CAS  Article  Google Scholar 

Barnard Z, Wakimoto H, Zaupa C, et al. Expression of FMS-like tyrosine kinase 3 ligand by oncolytic herpes simplex virus type I prolongs survival in mice bearing established syngeneic intracranial malignant glioma. Neurosurgery. 2012;71(3):741–8.

Article  Google Scholar 

Hoffmann D, Wildner O. Comparison of herpes simplex virus- and conditionally replicative adenovirus-based vectors for glioblastoma treatment. Cancer Gene Ther. 2007;14(7):627–39.

CAS  Article  Google Scholar 

Wakimoto H, Kesari S, Farrell CJ, et al. Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Res. 2009;69(8):3472–81.

CAS  Article  Google Scholar 

Cheema TA, Wakimoto H, Fecci PE, et al. Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model. Proc Natl Acad Sci USA. 2013;110(29):12006–11.

CAS  Article  Google Scholar 

Cheema TA, Kanai R, Kim GW, et al. Enhanced antitumor efficacy of low-dose etoposide with oncolytic herpes simplex virus in human glioblastoma stem cell xenografts. Clin Cancer Res. 2011;17(23):7383–93.

CAS  Article  Google Scholar 

Ning J, Wakimoto H, Peters C, et al. Rad51 degradation: role in oncolytic virus-poly(ADP-ribose) polymerase inhibitor combination therapy in glioblastoma. J Natl Cancer Inst. 2017;109(3):1–13.

Article  Google Scholar 

Kanai R, Rabkin SD, Yip S, et al. Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells. J Natl Cancer Inst. 2012;104(1):42–55.

CAS  Article  Google Scholar 

Nigim F, Esaki S, Hood M, et al. A new patient-derived orthotopic malignant meningioma model treated with oncolytic herpes simplex virus. Neuro Oncol. 2016;18(9):1278–87.

CAS  Article  Google Scholar 

Saha D, Wakimoto H, Peters CW, et al. Combinatorial effects of VEGFR kinase inhibitor axitinib and oncolytic virotherapy in mouse and human glioblastoma stem-like cell models. Clin Cancer Res. 2018;24(14):3409–22.

CAS  Article  Google Scholar 

Esaki S, Nigim F, Moon E, et al. Blockade of transforming growth factor-β signaling enhances oncolytic herpes simplex virus efficacy in patient-derived recurrent glioblastoma models. Int J Cancer. 2017;141(11):2348–58.

CAS  Article  Google Scholar 

Farrell CJ, Zaupa C, Barnard Z, et al. Combination immunotherapy for tumors via sequential intratumoral injections of oncolytic herpes simplex virus 1 and immature dendritic cells. Clin Cancer Res. 2008;14(23):7711–6.

CAS  Article  Google Scholar 

Sugawara K, Iwai M, Ito H, et al. Oncolytic herpes virus G47Δ works synergistically with CTLA-4 inhibition through dynamic intratumoral immune modulation. Mol Ther Oncol. 2021;22:129–42.

CAS  Article  Google Scholar 

Fan J, Jiang H, Cheng L, et al. Oncolytic herpes simplex virus and temozolomide synergistically inhibit breast cancer cell tumorigenesis in vitro and in vivo. Oncol Lett. 2021;21(2):99.

Article  Google Scholar 

Sugawara K, Iwai M, Yajima S, et al. Efficacy of a third-generation oncolytic herpes virus G47Δ in advanced stage models of human gastric cancer. Mol Ther Oncol. 2020;17:205–15.

CAS  Article  Google Scholar 

Fan J, Jiang H, Cheng L, et al. The oncolytic herpes simplex virus vector, G47Δ, effectively targets tamoxifen-resistant breast cancer cells. Oncol Rep. 2016;35(3):1741–9.

CAS  Article  Google Scholar 

Wang L, Ning J, Wakimoto H, et al. Oncolytic herpes simplex virus and PI3K inhibitor BKM120 synergize to promote killing of prostate cancer stem-like cells. Mol Ther Oncol. 2019;13:58–66.

Article  Google Scholar 

Yamada T, Tateishi R, Iwai M, et al. Neoadjuvant use of oncolytic herpes virus G47Δ enhances the antitumor efficacy of radiofrequency ablation. Mol Ther Oncol. 2020;18:535–45.

CAS  Article  Google Scholar 

Ito H, Ino Y, Todo T. Therapeutic efficacy of third generation oncolytic HSV-1 (G47delta) for glioma cells with stem cell property [abstract]. In: 19th annual meeting of the American Society of Gene and Cell Therapy, 2016.

Saha D, Martuza RL, Rabkin SD. Glioblastoma eradication by combination oncolytic immunovirotherapy and immune checkpoint blockade [abstract]. Mol Ther. 2017;25(5 Suppl 1):361.

Google Scholar 

Uchihashi T, Nakahara H, Fukuhara H, et al. Oncolytic herpes virus G47Δ injected into tongue cancer swiftly traffics in lymphatics and suppresses metastasis. Mol Ther Oncol. 2021;22:388–98.

CAS  Article  Google Scholar 

Yajima S, Sugawara K, Iwai M, et al. Efficacy and safety of a third-generation oncolytic herpes virus G47Δ in models of human esophageal carcinoma. Mol Ther Oncol. 2021;23:402–11.

CAS  Article  Google Scholar 

Inoue K, Ito H, Iwai M, et al. Neoadjuvant use of oncolytic herpes virus G47delta prevents stage advancement of tongue cancer. Cancer Sci. 2022;113:1422.

Article  Google Scholar 

Cheema TA, Fecci PE, Ning J, et al. Immunovirotherapy for the treatment of glioblastoma. OncoImmunology. 2014;3(1): e27218.

Article  Google Scholar 

Esaki S, Rabkin SD, Martuza RL, et al. Transient fasting enhances replication of oncolytic herpes simplex virus in glioblastoma. Am J Cancer Res. 2016;6(2):300–11.

CAS  PubMed  PubMed Central  Google Scholar 

Saha D, Rabkin SD, Martuza RL. Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma. J Immunother Cancer. 2020;8(Suppl 1): e000345.

Article  Google Scholar 

Todo T, Ino Y, Ohtsu H, et al. A phase I/II study of triple-mutated oncolytic herpes virus G47∆ in patients with progressive glioblastoma. Nat Commun. 2022;13(1):4119.

CAS  Article  Google Scholar 

Todo T. Results of phase ii clinical trial of oncolytic herpes virus G47delta in patients with glioblastoma [abstract no. ATIM-14]. Neuro Oncol. 2019;21(Suppl 6):vi4.

Article  Google Scholar 

留言 (0)

沒有登入
gif